Tagged with Fact

Canada Kennet Brysting, General Manager of Gilead Sciences Canada, Inc. outlines the strategic significance of the Canadian affiliate to Gilead Sciences globally, including its manufacturing and R&D footprint, the challenge of managing the financial costs of breakthrough therapies, and Gilead’s success in advancing innovative therapies in the fields of HIV and…

Austria Ard van der Meij, country president of Novartis Group Austria, the nation’s leading pharmaceutical company, discusses the advantages in Austria for innovative companies and the steps required to bolster the generics and biosimilars market share within the Austrian market to create a sustainable healthcare ecosystem for the long-term. Furthermore, he…

Austria Prof. Dr. Robin Rumler, country manager of Pfizer Austria, discusses the evolution of their operations, especially since taking over the TBE and meningitis vaccine production plant, as well as the challenges facing the entire Austrian healthcare system today. Furthermore, he provides solutions to create a sustainable future for Austrian healthcare,…

Austria Philipp von Lattorff, country managing director of Boehringer Ingelheim’s Regional Centre Vienna (RCV) discusses the current mandate of the center and the dynamic performance of its 33 members, as well as providing an overview of the soon to be completed 700 million EUR biopharmaceutical production plant to be built in…

Ukraine Dmytro Popov, the owner, founder and CEO Elfa Group, Ukraine’s leading cosmetics manufacturer, provides his insight into Elfa’s 20-year presence in the Ukrainian market, the company’s international growth strategies and how it can further strengthen its market positioning. Could you begin by introducing yourself and your company? “Our goal is…

Ukraine Dr. Paul Melekhov, vice president Eastern Europe at Pharmascience, Canada’s third largest generic company, provides insights into the unique history of Pharmascience in Ukraine and the pioneering market approach that he has been implementing in the country over the past 25 years. Leveraging its long-standing experience of the Ukrainian market,…

Indonesia Marlia Hayati and Joey Romana, President Director and Vice President Director at PT Darya-Varia Laboratoria, share insights about the company’s strong brand equity and pioneering manufacturing strategy. In 2016, the sales growth rate achieved by Darya-Varia Laboratoria was 11 percent, above market average. What business approach is the secret to…

Hong Kong William Lai YF, CEO of Fortune Pharmacal, discusses the Hong Kong OTC market, the company’s internationalization strategy, and its expanding manufacturing footprint. Could you please introduce us to Fortune Pharmacal? What sets you apart from other OTC companies? “We follow the highest standards by always exploring what the ‘big boys’…

Ukraine Anatoliy Novyk, founder and president of SMC Ecopharm, the only Ukrainian pharmaceutical company to be exclusively focused on its own original drug development, provides insights into Ecopharm’s promising expansion strategy, which should be significantly propelled by the company’s upcoming GMP-certified manufacturing plant. He also provides an in-depth look into their…

Indonesia Aylie Widjaja, managing director at Exeltis Indonesia, shares her excitement about developing the company’s footprint in Indonesia, making it a manufacturing hub for Asia, and highlights the challenges in navigating the public market. How do you see the Indonesian healthcare landscape evolving? “We have to give better options to patients…

Ukraine Filya Zhebrovska, chairman of the supervisory board of Farmak and the company’s general director between 1995 and 2017, provides insights into the strategy she has followed to establish Farmak as Ukraine’s largest domestic company and the market leader in the country since 2010. She also documents the impact of the…

Colombia Emilio Sardi, vice-president of Tecnoquimicas, the local champion in production and distribution of generic pharmaceutical drugs, shares his insights on his current priorities to enter the biotechnology field, grow their international operations focusing on Central American countries and further strengthen the company’s exceptional capacity to launch new products.   The…